13122-23-1

Upstream product

• 22509-74-6 N-ethoxycarbonylphthalimide 
• 671-42-1 D(+)-α-Amino-ε-caprolactam 
• 21568-87-6 L(-)-α-Amino-ε-caprolactam 
• 85-44-9 phthalic anhydride 
• 29426-64-0 (R)-α-amino-ε-caprolactam hydrochloride 

Downstream Products

• 1334523-97-5 (+)-(S)-N-11-dimethylethoxyundecyl-(N-3,5-dinitrobenzoyl)-3-amino-ε-caprolactam 
• 1334523-91-9 (+)-(S)-(N-3,5-dinitrobenzoyl)-3-amino-N-10-undecenyl-ε-caprolactam 
• 1334523-94-2 (N-3,5-dinitrobenzoyl)-3-amino-N-10-undecenyl-ε-caprolactam 

Relevant academic research and scientific papers

NEW CRBN MODULATORS

Disclosed are degraders, pharmaceutical compositions containing them, and methods of making and using the degraders to treat diseases and disorders characterized by dysregulated or dysfunctional protein activity that can be targeted by cereblon.

Synthesis, central nervous system activity and teratogenicity of a homothalidomide

The optical isomers of α-phthalimidoadipinimide (1) were synthesized by a route based on D(+)- and L(-)-amino-ε-caprolactam (5) as synthon. The isomers of 1 were obtained in high yields by treating D(+)- and L(-)-amino-ε-caprolactam (5) with N-carboethoxyphthalimide (4), followed by oxidation with benzeneseleninic anhydride (7). The teratogenic potency of both isomers of 1 was studied by the HET-(Hen's Egg Test); 1 caused distinctly lower teratogenic effects in contrast to thalidomide (2). D(-)-1 and L(+)-1 showed sedative effects with a lower activity than 2. Both are more stable in alkaline solution at the same time with a smaller tendency for racemization.